Drug Trial Radar · NCT04738812
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,330
Actual
Start
Apr 21, 2022
Primary completion
Nov 12, 2025
Study completion Nov 12, 2025
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- European Union; European and Developing Countries Clinical Trials Partnership (EDCTP)
- First posted
- Feb 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DATURA trial is a phase III, multicenter, two-arm, open-label, randomized superiority trial to compare the efficacy and the safety of an intensified tuberculosis (TB) regimen versus standard TB treatment in HIV-infected adults and adolescents hospitalized for TB with CD4 ≤ 100 cells/μL over 48 weeks: * Intensified TB treatment regimen: increased doses of rifampicin and isoniazid together with standard-dose of pyrazinamide and ethambutol for 8 weeks in addition to prednisone for 6 weeks and albendazole for 3 days * WHO standard TB treatment regimen. The continuation phase of TB treatment will be identical in the two arms: 4 months of rifampicin and isoniazid at standard doses.
Conditions
- Tuberculosis
- HIV-1-infection
- Immuno-Deficiency
Interventions
Intensified TB treatment (initial phase)Drug
8 weeks of RHEZ with high dose of rifampicin (R) and isoniazid (H). Fixed dose combination (FDC) of RHZE with the addition of FDC of RH and single caps of R. 6 weeks of prednisone with tapering doses. 3 days of albendazole 400 mg.
WHO standard TB treatment (initial phase)Drug
8 weeks of RHEZ with FDC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of all causes deathTime frame: Up to 48 weeks
Locations
6 sites in 6 countries. Site status is shown where the registry gives one.
National Center for HIV/AIDS, Dermatology and STD (NCHADS)
Phnom Penh, Cambodia
Jamot Hospital
Yaoundé, Cameroon
Ignace Deen Hospital
Conakry, Guinea
MACHAVA Hospital
Maputo, Mozambique
Mbarara Regional Referral hospital
Mbarara, Uganda
University Teaching Hospital
Lusaka, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.